Supplier News: Evotec, Fujifilm, Olon & More
The latest from CDMOs, CMOs, and suppliers featuring Evotec, Fujifilm Diosynth Biotechnologies and Olon.
Chemicals/Chemical API Manufacturing
* Evotec To Sell Chemical API Mfg Facility To Investment Firm
* Olon Provides Update on Ultra-Potent Mfg Facility
Biologics Manufacturing
* Fujifilm Diosynth Launches First Phase of Biomanufacturing, Fill–Finish Expansion
Chemicals/Chemical API Manufacturing
Evotec To Sell Chemical API Mfg Facility To Investment Firm
Evotec has announced the sale of its chemical active pharmaceutical ingredient (API) manufacturing site, Evotec DS GmbH, located in Halle/Westphalia, Germany, to Monacum Partners GmbH, a Munich, Germany-based private equity firm.
This transaction forms part of Evotec’s “Priority Reset” initiative launched in April 2024, which aims to foster profitable growth by refining the company’s operational footprint and focusing on its primary growth sectors and core competencies.
Under the agreement, all business operations and the entire workforce at Evotec DS will transition to Monacum Partners and continue business as DAPIN GmbH (Deutsche API & Intermediates). Financial terms of the transaction were not disclosed.
Source: Evotec
Olon Provides Update on Ultra-Potent Mfg Facility
Olon, a CDMO of small-molecule and biologic drug substances, has announced the schedule for the construction of its new EUR-25-million ($27-million) facility dedicated to ultra-potent compounds in Rodano (Milan), Italy.
The company has already successfully completed the installation and validation of a new-small scale production area within the facility. The installation of the plant for large-scale production will also be completed shortly, with completion scheduled for January 2025. The commercial-scale line will be fully integrated with the small-scale line. The new plant, designed to produce payloads, linker payloads, and ultra-potent APIs, is now ready to accommodate small-scale GMP production.
Source: Olon
Biologics Manufacturing
Fujifilm Diosynth Launches First Phase of Biomanufacturing, Fill–Finish Expansion
Fujifilm Diosynth Biotechnologies, a CDMO of biologics, has launched the first phase of its expansion at its site in Hillerød, Denmark, for the production of biologic drug substances. The company reported that it is ready to bring the new production capacity into operation.
The first phase adds six mammalian cell bioreactors, bringing the total capacity at the Hillerød site to 12 x 20,000-L bioreactors. A previously announced major capital investment will support the next phase, which will include an additional 8 x 20,000-L bioreactors and two downstream processing streams. By mid-2025, fill-finish production is scheduled to commence, with full expansion expected to be in operation by 2026, increasing the site’s footprint to approximately 51,500 square meters and creating up to 2,200 jobs. The Hillerød site has signed a 10-year Power Purchase Agreement to source all electricity from renewable sources.
